Newman K A, Reed W P, Schimpff S C, Bustamante C I, Wade J C
University of Maryland Cancer Center, University of Maryland Hospital, Baltimore 21201.
Support Care Cancer. 1993 Mar;1(2):92-7. doi: 10.1007/BF00366902.
Hickman catheters were the major venous access devices utilized at the University of Maryland Cancer Center from November 1978 to 1987. This study provided an opportunity to standardize insertion technique, to manage catheter-related activities and daily maintenance procedures in order to examine the progression of Hickman-catheter-related problems, to identify those factors that may minimize them, and to develop guidelines for the management and prevention of complications and malfunctions. In all, 690 Hickman catheters (368 double lumens) were placed in patients with acute leukemia and other cancers: 401 catheters were placed in patients with leukemia; 269 were placed during neutropenia; and 230 at platelet counts of < 50,000/microliters. Two surgeons inserted 490 catheters, and the remaining 200 were placed by a group of rotating surgeons. All catheters were placed with the intention that they would remain in place as long as clinically necessary. Total Hickman catheter days were 134273. Infectious complications included exit site infections (160), tunnel infections (46) and bacteremias (397). There were 438 instances of noninfectious complications including thrombosis, lack of function, catheter migration, fracture and hemorrhage. Recommendations for prevention and treatment of Hickman-catheter-related complications include the development of a select group committed to placement, daily maintenance and management of problems; prompt removal of catheters with Candida sp. fungemia and bacteremia due to Bacillus sp. or a bacteremia that persists for > 48 h after initiation of appropriate antibiotics, tunnel infections or Hickman-catheter-associated thrombosis. The majority of bacteremias and exit site infections can be effectively treated with antibiotics and local care.
1978年11月至1987年期间,希克曼导管是马里兰大学癌症中心使用的主要静脉通路装置。本研究提供了一个机会,以规范插入技术,管理与导管相关的活动和日常维护程序,从而检查希克曼导管相关问题的进展情况,确定那些可能将这些问题最小化的因素,并制定管理和预防并发症及故障的指南。总共为急性白血病和其他癌症患者置入了690根希克曼导管(368根双腔导管):401根导管置入白血病患者体内;269根在中性粒细胞减少期间置入;230根在血小板计数<50,000/微升时置入。两名外科医生置入了490根导管,其余200根由一组轮转外科医生置入。所有导管置入的目的都是只要临床需要就一直保留在原位。希克曼导管总使用天数为134273天。感染性并发症包括出口部位感染(160例)、隧道感染(46例)和菌血症(共397例)。有438例非感染性并发症,包括血栓形成、功能丧失、导管移位、断裂和出血。希克曼导管相关并发症的预防和治疗建议包括组建一个专门负责导管置入、日常维护和问题处理的团队;对于念珠菌血症、芽孢杆菌属导致的菌血症或在开始使用适当抗生素后持续>48小时的菌血症、隧道感染或希克曼导管相关血栓形成,应及时拔除导管。大多数菌血症和出口部位感染可以通过抗生素和局部护理得到有效治疗。